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these data suggest that Ngb is part of the E 2 signaling mech-
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H 2 O 2 -induced neurotoxicity. 
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 Introduction 
 Neuroglobin (Ngb), the third member of the globin 
family  [1] , is a monomeric hexa-coordinated heme pro-
tein of 17 kDa expressed not only in neurons of the cen-
tral and peripheral nervous systems, but also in the gas-
trointestinal tract and in endocrine organs  [1–18] . Re-
cently, Ngb has also been detected in human glioblastoma 
cell lines  [17] and in quiescent astrocytes of the healthy 
seal brain  [15] . Although Ngb occurs at relatively low con-
centrations (  M ) in a wide range of tissues, Ngb is found 
at relatively high concentrations in highly metabolically 
active cells and certain specialized cells, such as neurons 
of the hypothalamus, and particularly in retinal rod cells 
where its concentration has been estimated to be up to 
100   M  [18–21] . Ngb binds several ligands, including di-
atomic gaseous ligands, and displays (pseudo-)enzymatic 
properties  [1, 3, 6, 10, 22–33] . The  P 50 value for O 2 binding 
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 Abstract 
 Although discovered in 2000, neuroglobin (Ngb) functions 
are still uncertain. A contribution to the role played by Ngb 
in neurons could certainly derive from the identification of 
Ngb endogenous modulators. Here, we evaluate the possi-
bility that Ngb could be regulated by 17  -estradiol (E 2 ) sig-
naling in both SK-N-BE human neuroblastoma cell line and 
mouse hippocampal neurons. 1 n M E 2 rapidly induced a 
300% increase in Ngb levels in both models. The E 2 effect 
was specific, being not induced by testosterone or dihy-
drotestosterone. The E 2 -induced Ngb increase requires es-
trogen receptor (ER)   , but not ER  , as evaluated by the mi-
metic effect of ER  -specific agonist DPN and by the block-
age of E 2 effect in ER  -silenced SK-N-BE cells. Furthermore, 
both rapid (15 min) ER  -dependent activation of p38/MAPK 
and transcriptional ER  activity were required for the estro-
genic regulation of Ngb. Finally, E 2 exerted a protective ef-
fect against H 2 O 2 -induced neuroblastoma cell death which 
was completely prevented in Ngb-silenced cells. Overall, 
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to Ngb has been reported to range between 2 and 10 Torr 
depending on pH, temperature, and the redox state of the 
cell  [1, 22–24, 32] .
 Although discovered in 2000  [1] , the cell function(s) of 
Ngb is still controversial. Indeed, the O 2 supply by Ngb to 
the mitochondria of the metabolically active neurons and 
retinal rod cells is highly debated  [1, 15, 19, 33, 34] . In vi-
tro, Ngb has been reported to scavenge nitrogen monox-
ide (NO) in the presence of high O 2 levels  [25, 28, 35] ; 
however, at low O 2 conditions Ngb may react with NO 2 – 
resulting in the formation of NO  [36] . Therefore, the pro-
tective role of Ngb against NO in vivo is controversial  [32, 
33, 37] . Although in vitro Ngb does not react with hydro-
gen peroxide (H 2 O 2 )  [25, 30] and the Ngb-NO 2 adduct 
reacts with H 2 O 2 facilitating the nitration of aromatic 
substrates  [30] , the correlation between reactive oxygen 
species formation/decomposition and Ngb expression in 
vivo is debated  [15, 38] . Moreover, Ngb has been reported 
to interact with several proteins (see  [ 15] ). In particular, 
Ngb binding to the G  protein inhibits GDP dissociation, 
thereby protecting cells from apoptosis  [39, 40] . Recently, 
in silico simulations indicate Ngb capability to reduce cy-
tochrome  c released from mitochondria suggesting its 
protective role against programmed cell death  [19, 41–43] .
 Although Ngb properties are highly debated  [12, 15, 
19, 33, 44] , it is unlikely that Ngb has so many distinct 
roles  [15] ; nevertheless, there is no doubt that Ngb is ben-
eficial to neurons  [15] . In vivo experiments, using trans-
genic rodents, have shown that increased levels of Ngb 
significantly protect both heart and brain tissues from 
hypoxic insult, whereas decreased Ngb levels lead to an 
exacerbation of tissue death  [45–47] . In this way, Ngb 
could protect neurons from hypoxic insult by modulating 
the activation of the apoptotic cascade  [19, 41] . A signifi-
cant contribution to highlight the role played by Ngb in 
neuroprotection could derive from the identification of 
Ngb endogenous modulator(s) (e.g., hormones and neu-
rotransmitters), but, as far as we know, no Ngb involve-
ment in the hormone signal transduction pathways has 
been identified yet.
 Female sex steroid hormones could represent good 
candidates as Ngb modulators. Indeed, in addition to 
their well-established role in reproductive organs, es-
trogens affect areas of the brain that are not primarily 
involved in reproduction  [48] . Growing evidence do-
cuments profound effects of estrogens on learning, mem-
ory, and mood as well as neurodevelopmental and 
neurodegenerative processes  [49, 50] . Although most 
studies have been conducted on females, there is mount-
ing recognition that estrogens play important roles in the 
male brain, where they can be generated from circulating 
testosterone by local aromatase or synthesized de novo by 
neurons and glia  [51] . Several sources of evidence con-
firm that estrogens serve as neurotrophic and neuropro-
tective agents. Notably, 17  -estradiol (E2) attenuates the 
toxicity of the amyloid-  peptide and glutamate in a hip-
pocampal cell line  [52] . In addition, estrogen therapy in 
post-menopausal women is associated with decreased
incidence and enhanced recovery from ischemic stroke 
 [51] . The protective effects of estrogens have been widely 
reported in different types of neuronal cells against a va-
riety of insults, including H 2 O 2  [53, 54] , serum depriva-
tion  [55] , oxygen-glucose deprivation  [56] , and iron  [57] . 
Due to myriad and often tissue-specific estrogen effects, 
the precise molecular events that mediate these protec-
tive actions are not fully understood. Here, we evaluate 
the possibility that Ngb could be part of 17  -estradiol-
induced signals and effects in neuronal cells.
 Materials and Methods 
 Reagents 
 E 2 , testosterone (T), 5  -androstan-17  -ol-3-one (dihydrotes-
tosterone, DHT), naringenin (Nar), insulin-like growth factor 1 
(IGF-1), actinomycin D (Act), cycloheximide (Cxm), Pen-Strep 
solution, H 2 O 2 , RPMI-1640 media without phenol red, and char-
coal-stripped fetal calf serum, the palmitoyl acyltransferase 
(PAT) inhibitor 2-bromohexadecanoid acid (2-Br-palmitate; 
2-Br), the protease inhibitor cocktail, and the bovine serum albu-
min fraction V (BSA) were purchased from Sigma-Aldrich (St. 
Louis, Mo., USA).
 Optimem, Hank’s buffer salt solution (HBSS 1 ! ), Neurobasal 
medium, B27 serum-free supplement, and GlutaMAX-I were pur-
chased from Gibco-BRL (Gaithersburg, Md., USA). The p38 in-
hibitor SB 203 580 (SB), the AKT inhibitor, and the IGF-1 receptor 
(IGF-1R) inhibitor picropodophyllin (PPP) were obtained from 
Calbiochem (San Diego, Calif., USA). The E 2 antagonist fulves-
trant (ICI 182,780, ICI), the estrogen receptor (ER)   -selective
agonist 4,4  ,4   -(4-propyl-[ 1 H]-pyrazole-1,3,5-triyl)trisphenol 
(PPT), the ER  -selective agonist 2,3-bis(4-hydroxyphenyl)pro-
pionitrile (DPN), and the ER  -selective antagonist (R,R)-5,11-
diethyl-5,6,11,12-tetrahydro-2,8-chrysenediol (THC) were ob-
tained from Tocris (Ballwin, Mo., USA). Bradford protein assay 
was obtained from Bio-Rad Laboratories (Hercules, Calif., USA). 
The human recombinant ER  and ER  were obtained by Pan-
Vera (Madison, Wisc., USA). The anti-phospho-ERK1/2, anti-
AKT, anti-ER  (MC20), anti-ER  (H150), anti-caspase-3, anti-
poly(ADP-ribose)polymerase (PARP), and anti-ERK1/2 antibod-
ies were obtained from Santa Cruz Biotechnology (Santa Cruz, 
Calif., USA). The polyclonal anti-phospho-AKT, anti-phospho-
p38, and anti-p38 antibodies were purchased from New England 
Biolabs (Beverly, Mass., USA). The monoclonal anti-human Ngb 
(13C8) was purchased from Abcam (Cambridge, UK). The anti-
  -tubulin was purchased from MP Biomedical (Solon, Ohio, 
USA). The chemiluminescence reagent for Western blot ECL was 
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obtained from GE Healthcare (Little Chalfont, UK). All the other 
products were from Sigma-Aldrich. Analytical or reagent grade 
products were used without further purification.
 Cells 
 The human SK-N-BE neuroblastoma cell line was routinely 
grown in air containing 5% CO 2 in modified, phenol red-free, 
RPMI-1640 medium containing 10% (v/v) charcoal-stripped fetal 
calf serum,  L -glutamine (2.0 m M ), Pen-Strep solution (penicillin 
100 U/ml, and streptomycin 100 mg/ml). Cells were passaged ev-
ery 2 days. Cells were grown to approximately 70% confluence in 
6-well plates before stimulation.
 Hippocampal neurons were obtained from E18 mouse embry-
os after isolating the hippocampus in Ca 2+ - and Mg 2+ -free HBSS 
1 ! . Mice were treated following the guidelines of the Council of 
Europe Convention ETS123, recently revised as indicated in the 
Directive 86/609/EEC. In addition, all protocols were approved by 
the Institutional Animal Care and Use Committee of CSIC-Cajal 
Institute (Madrid, Spain). Once 8–10 embryonic hippocampi 
were obtained, they were finely cut, washed twice in HBSS 1 ! 
buffer, and incubated in 0.1 mg/ml trypsin solution and 1 mg/ml 
DNAse (Roche Diagnostics GmbH, Mannheim, Germany) for 15 
min at 37  °  C. Trypsin and DNAse were then eliminated by wash-
ing 3 times, with HBSS 1 ! , and the cut tissue was then triturated 
using a siliconized pipette. Cells were counted and plated in poly-
lysine-coated (1 mg/ml) 6-well plates containing phenol red-free 
neurobasal medium supplemented with 2% (v/v) B27 serum-free 
supplement, 0.25% (v/v) GlutaMAX-I, and 1% (v/v) penicillin/
streptomycin solution. Neurons were maintained under these 
conditions for 3 days at 5% CO 2 and 37  °  C.
 Cells were simultaneously treated with vehicle (ethanol/PBS
1: 10, v/v) and/or E 2 (0.1–1,000 n M ), PPT (0.1–100 n M ), DPN (0.1–
100 n M ), T (0.1–1,000 n M ), DHT (0.1–1,000 n M ), IGF-1 (100 ng/
ml), and H 2 O 2 (50   M ). When indicated, the anti-estrogen ICI
(1   M ), the PAT inhibitor 2-Br (10   M ), the AKT inhibitor (1   M ), 
the p38 inhibitor SB (5   M ), the ER  inhibitor THC (1   M ), the 
IGF-1R inhibitor PPP (100 n M ), and the transcription inhibitor 
Act (1   g/ml) were added 30 min before E 2 or IGF-1 administra-
tion. The translational inhibitor Cxm (10   g/ml), was added 1 h 
before E 2 administration.
 Cell Viability 
 SK-N-BE cell lines were grown to 70% confluence in 6-well 
plates and stimulated either with vehicle or E 2 (1 n M ) or THC
(1   M ). After 24 h of stimulation, cells were treated either with 
vehicle or with H 2 O 2  50   M for 24 h. After treatment, cells were 
harvested with trypsin, and counted with Beckman Coulter Mod-
el ZM electronic particle (Palo Alto, Calif., USA).
 Transfection of Short Interfering RNA 
 SK-N-BE cells, reaching 40–60% confluence, were transfected 
in a serum-free condition with either Stealth RNAi TM Ngb-silenc-
ing RNA or ER  -silencing RNA (siRNA; Invitrogen) according 
to the manufacturer’s instructions, using oligofectamine (Invit-
rogen) as the transfection reagent. The sequence used for Ngb 
oligonucleotides was 5  -CGUGAUUGAUGCUGCAGUGACC-
AAU-3  ; the sequence used for ER  oligonucleotides was 5  -
GAAGAACUCUUUGCCCGGAAAUUUA-3  . The mismatch
sequences used as a control were 5  -UGUGAUUUAUGGUGC-
AGUAACCAAC-3  and 5  -GAAUCAUUCCGUGC CA AG UA G-
A UUA-3  for Ngb and ER  si-RNA, respectively. Briefly, oligo-
fectamine and oligonucleotides (400 and 200 p M for Ngb siRNA 
and ER  siRNA, respectively) were mixed with Optimem. The 
mixture was incubated for 20 min at room temperature, diluted 
with Optimem, and added to the cell medium for 4 h at 37  °  C. The 
medium was added to cells to reach the growing conditions (i.e., 
10% (v/v) serum).
 To evaluate the effective silencing of Ngb and ER  , total pro-
teins from cells transfected with MOCK (control), with scramble 
(mismatch sequence, data not shown), and with Ngb or ER  oli-
gonucleotides were extracted 48 h after transfection, and Ngb and 
ER  expression was tested by Western blot analysis using anti-
Ngb and anti-ER  antibodies.
 Western Blot Assays 
 After stimulation, the SK-N-BE cell line and hippocampal 
neurons were lysed and solubilized in 0.125  M Tris, pH 6.8, con-
taining 10% (w/v) SDS and the protease inhibitor cocktail, then 
the cell lysates were boiled for 2 min. Total proteins were quanti-
fied using the Bradford protein assay. Solubilized proteins (20   g) 
were resolved by 7 or 15% SDS-PAGE at 100 V for 1 h at 25  °  C and 
then electrophoretically transferred to nitrocellulose for 45 min 
at 100 V and 4   °   C. The nitrocellulose was treated with 3% (w/v) 
BSA in 138 m M NaCl, 25 m M Tris, pH 8.0, at 25   °   C for 1 h and
then probed overnight at 4  °  C either with anti-Ngb (final dilution 
1: 1,000) or anti-ER  MC-20 (final dilution 1: 500) or anti-ER  
H-150 (final dilution 1: 3,000) or anti-caspase-3 (final dilution
1: 1,000) or anti-PARP (final dilution 1: 500) or anti-phospho-
ERK1/2 (final dilution 1: 200) or anti-phospho-AKT (final dilu-
tion 1: 1,000) or anti-phospho-p38 (final dilution 1: 1,000). The ni-
trocellulose was stripped by Restore Western Blot Stripping Buf-
fer (Pierce Chemical, Rockford, Ill., USA) for 10 min at room 
temperature and then probed with anti-  -tubulin (final dilution
1: 1,000) to normalize total lysate. Moreover, the nitrocellulose in-
cubated with either anti-phospho-ERK1/2 or anti-phospho-AKT 
or anti-phospho-p38 was stripped and probed with anti-ERK1/2 
(final dilution 1: 200), anti-AKT (final dilution 1: 100) and anti-
p38 (final dilution 1: 1,000), respectively. To evidence ER  and 
ER  levels, electrophoresis was performed in the presence of 5 ng 
of recombinant ER  and ER  . Antibody reaction was visualized 
with chemiluminescence Western blot detection reagent.
 Densitometric analyses were performed by ImageJ software 
for Windows. The densitometry quantification of protein was 
normalized to tubulin.
 Statistical Analysis 
 A statistical analysis was performed by using ANOVA fol-
lowed by Tukey-Kramer post-test with the GraphPad InStat3 soft-
ware system for Windows. In all cases, p  ! 0.05 was considered 
significant.
 Results 
 E 2 Specifically Increases Ngb Levels in Neurons 
 Figure 1 shows that E 2 stimulation induced a time- and 
dose-dependent increase in Ngb levels in SK-N-BE cells 
( fig. 1 A, B). The E 2 (10 n M ) effect on Ngb levels started 30 
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min after stimulation being significant 1 h after stimula-
tion and remained constant 24 h after hormone stimula-
tion. The E 2 dose-response curve was bell-shaped with a 
maximum effect at physiological E 2 concentrations (i.e., 
1–10 n M ; 24 h stimulation).
 In contrast, the male sex steroid hormone DHT and 
the common precursor of E 2 and DHT, T, did not modify 
Ngb levels at any tested concentration (data not shown), 
suggesting the specificity of the E 2 effect. These data were 
confirmed in freshly isolated mouse hippocampal neu-
rons ( fig. 1 C, D). Indeed, in these primary neurons, the 
E 2 effect was rapid (1 h), persistent (24 h) ( fig. 1 C), and 
specific in that neither DHT nor T were able to increase 
Ngb levels at any tested concentration (data not shown). 
In addition, even in mouse hippocampal neurons, 10 n M 
E 2 increased Ngb levels which remained significantly 
higher than control cells even at higher E 2 concentrations 
( fig. 1 D). In line with the slight differences found in the 
E 2 concentration to obtain the maximum effect in both 
cell types, 1 and 10 n M were used in the consecutive ex-
periments to stimulate the SK-N-BE cell line and hippo-
campal neurons, respectively.
 ER  was necessary for E 2 -induced increase in Ngb lev-
els. The pretreatment of SK-N-BE cells with the pure E 2 
antagonist, ICI, completely prevented the E 2 effect on 
Ngb levels ( fig. 2 A), suggesting an ER-mediated mecha-
nism. As SK-N-BE cells contain high ER  and low ER  
levels ( fig. 2 B), cells were stimulated with either the spe-
cific ER  agonist PPT or the specific ER  agonist DPN 
to discriminate the role of each ER isoform in the E 2 -in-
duced Ngb level increase. Only 1 and 10 n M DPN mim-
icked the E 2 effect on Ngb levels ( fig. 2 C), whereas PPT 
was unable to increase Ngb levels, at any concentration 
investigated ( fig. 2 D). This result was confirmed by cell 
pretreatment with the specific ER  inhibitor THC, which 
completely prevented the E 2 effect ( fig. 2 C). Furthermore, 
the decrease of ER  protein level by ER  SiRNA transfec-
tion caused an impairment of the E 2 ability to increase 
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 Fig. 1. Effect of 17  -estradiol (E 2 ) on Ngb 
protein levels in SK-N-BE human neuro-
blastoma cell line ( A ,  B ) and in mouse hip-
pocampal primary neurons ( C ,  D ).  A ,  C 
Time-course analysis of E 2 treatment (10 
n M ) on Ngb levels.  B ,  D E 2 dose-dependent 
(0.1–1,000 n M ) effect on Ngb levels (24 h of 
stimulation). The amount of protein was 
normalized by comparison with tubulin 
levels. The data are typical Western blots 
of five independent experiments (top pan-
els); densitometric analysis related to E 2 
dose- and time-dependent experiments 
(bottom panels). Data are means  8 SD of 
five different experiments. p  !  0.001 was 
calculated with ANOVA followed by 
Tukey-Kramer post-test.  A ,  C a significant 
vs. 0 h and b vs. 0.5 h;  B ,  D a vs. 0, b vs. 0.1, 
c vs. 1, and d vs. 10 n M . 
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 Fig. 2. Impact of estrogen receptors (ER)   and   on Ngb protein 
expression in SK-N-BE human neuroblastoma cell line.  A West-
ern blot analysis of Ngb levels in cells stimulated for 24 h with 
either vehicle or E 2 (1 n M ) and/or the ER inhibitor ICI 182,870 
(ICI; 1   M ).  B ER isoform levels in non-stimulated cells compared 
to recombinant proteins (5 ng).  C Analysis of Ngb levels in cells 
stimulated for 24 h with either vehicle, E 2 (1 n M ), the ER  agonist 
2,3-bis(4-hydroxyphenyl)propionitrile (DPN; 1–100 n M ) or the 
ER  -selective antagonist (R,R)-5,11-diethyl-5,6,11,12-tetrahy-
dro-2,8-chrysenediol (THC; 1   M ).  D Analysis of Ngb levels in 
cells stimulated for 24 h with either vehicle, E 2 (1 n M ) or the ER  
agonist 4,4  ,4   -(4-propyl [ 1 H]-pyrazole-1,3,5-triyl)trisphenol 
(PPT; 1–100 n M ).  E Analysis of Ngb and ER  levels in cells trans-
fected with either MOCK (control) or ER  small interference 
mRNA (si-ER  ) in the absence or presence of E 2 (1 n M ).  F Analy-
sis of Ngb levels in cells stimulated for 24 h with either vehicle, E 2 
(1 n M ) or naringenin (Nar; 0.01–10   M ). The amount of proteins 
was normalized by comparison with tubulin levels. The data are 
typical Western blots of four independent experiments; densito-
metric analyses related to DPN, PPT, and Nar dose-dependent 
experiments ( C ,  D and  F bottom panels). Data are means  8 SD of 
four different experiments. p  !  0.001 was calculated with ANOVA 
followed by Tukey-Kramer post-test.  C ,  D a significant vs. vehicle, 
b vs. E 2 , c vs. 1, and d vs. 10 n M .  F a significant vs. vehicle, b vs. E 2 , 
c vs. 0.01, and d vs. 0.1   M . 
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Ngb levels ( fig. 2 E). A further confirmation of the ER  
involvement in the effect of E 2 effects derives from the 
results obtained using the flavonoid Nar ( fig. 2 F). Indeed, 
we previously reported that this flavonoid is a partial an-
tagonist of E 2 in the presence of ER   [58] and an E 2 mi-
metic in the presence of ER   [59] .  Figure 2 F shows that, 
like E 2 , 0.1   M Nar was sufficient to increase Ngb levels. 
This effect persisted at Nar high concentrations (i.e., 1 
and 10   M ). ER  was also necessary for the E 2 -induced 
Ngb increase in mouse primary neurons ( fig. 3 ). In these 
cells, containing a similar amount of ER  and ER  
( fig. 3 A), ICI prevented the E 2 effect ( fig. 3 B), DPN mim-
icked the E 2 effect ( fig. 3 C), whereas PPT was unable to 
increase Ngb levels ( fig. 3 D). Cell pretreatment with the 
specific ER  inhibitor THC further confirmed these re-
sults ( fig. 3 E).
 Mechanism Involved in the E 2 -Induced Increase of 
Ngb Levels in Neurons 
 ERs are ligand-activated transcription factors which 
possess both transcriptional and extranuclear activities 
 [48] . Thus, we evaluated the impact on the E 2 -induced 
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 Fig. 3. Impact of estrogen receptors (ER)   and   on Ngb protein 
expression in mouse hippocampal primary neurons.  A ER isoform 
levels in non-stimulated cells compared to recombinant proteins 
(5 ng).  B Western blot analyses of Ngb levels in cells stimulated for 
24 h with either vehicle or E 2 (10 n M ) and/or the ER inhibitor ICI 
182,870 (ICI; 1   M ).  C Analyses of Ngb levels in cells stimulated 
for 24 h with either vehicle, E 2 (10 n M ) or the ER  agonist 2,3-bis(4-
hydroxyphenyl)propionitrile (DPN; 0.1–100 n M ).  D Analyses of 
Ngb levels in cells stimulated for 24 h with either vehicle, E 2 (10 
n M ) or the ER  agonist 4,4  ,4   -(4-propyl [ 1 H]-pyrazole-1,3,5-tri-
yl)trisphenol (PPT; 0.1–100 n M ).  E Analyses of Ngb levels in cells 
stimulated for 24 h with either vehicle, E 2 (10 n M ) and/or the ER  -
selective antagonist (R,R)-5,11-diethyl-5,6,11,12-tetrahydro-2,8-
chrysenediol (THC; 1   M ). The amount of proteins was normal-
ized by comparison with tubulin levels. Typical blots of five inde-
pendent experiments are shown; densitometric analyses related to 
DPN and PPT dose-dependent experiments ( C ,  D bottom panels). 
Data are means  8 SD of five different experiments.  *  p  !  0.001 
was calculated with ANOVA followed by Tukey-Kramer post-test 
with respect to vehicle-treated samples. 
 17  -Estradiol Signaling and Neuroglobin Neurosignals 2010;18:223–235 229
Ngb levels of the transcription inhibitor Act, the transla-
tion inhibitor Cxm, and the ER membrane localization 
inhibitor 2-Br  [60] . Although the Ngb promoter sequence 
analysis (accession No. 12,581 from Transcriptional Reg-
ulatory Element Database http://rulai.cshl.edu/cgibin/
TRED/tred.cgi?process=home) indicates that no canon-
ical estrogen-responsive element (ERE) is present, SK-N-
BE cell pretreatment for 24 h with Act completely pre-
vented the E 2 effect on Ngb levels ( fig.  4 A). Similarly, 
Cxm ( fig. 4 B) and 2-Br ( fig. 4 C) impaired the increase of 
Ngb levels induced by E 2 , suggesting that both transcrip-
tional and extranuclear mechanisms contribute to E 2 ef-
fects. This prompted us to evaluate which signal trans-
duction cascade was activated by E 2 in neurons. After 15 
min of stimulation with 1 n M E 2 , an increase of AKT and 
p38 phosphorylation in SK-N-BE cells was observed 
( fig. 5 A, B). The E 2 -induced activation of these kinases 
was still present 1 h after E 2 stimulation ( fig. 5 A, B), but 
only the E 2 -induced p38 phosphorylation persisted 24 h 
after hormone stimulation (data not shown). By 30 min 
after 1 n M E 2 stimulation, the ERK1/2 phosphorylation 
status decreased ( fig. 5 A, B), in agreement with previous 
data obtained in cortical neurons  [61] . The cell pretreat-
ment with either AKT or p38 or ERK1/2 inhibitors sug-
gested that neither AKT nor ERK1/2 are involved in the 
E 2 -induced increase of Ngb levels (data not shown), 
whereas p38 activation was required for both rapid (i.e., 
1 h) and long term (i.e., 24 h) E 2 effects on Ngb levels 
( fig. 5 C, D). Similarly, only p38 inhibitor prevents an E 2 -
induced Ngb level increase in hippocampal neurons 
(data not shown). Notably, the SK-N-BE cell transfection 
with ER  SiRNA reduced both ER  levels and the E 2 
ability to induce p38 phosphorylation ( fig. 5 E). On the 
other hand, ER  SiRNA did not impair the E 2 -induced 
AKT activation (data not shown), suggesting that ER  
could be the molecular mediator of AKT activation in 
these cells.
 Since it has been reported that several actions of E 2 in 
the nervous system involve cross-talk between ER  and 
the IGF-1 receptor  [62] , we evaluated the possibility that 
the ER  -dependent E 2 -induced p38 phosphorylation and 
the Ngb-increased levels are dependent on the ER  -IGF-1 
receptor cross-talk. IGF-1 is more efficient than E 2 to ac-
tivate AKT phosphorylation and cell pretreatment with 
PPP, the IGF-1 receptor inhibitor, strongly prevented both 
IGF-1 and E 2 effects on AKT activation ( fig. 5 F), confirm-
ing that cross-talk between the IGF-1 receptor and ERs is 
important for AKT activation. However, IGF-1 was un-
able to increase p38 phosphorylation and PPP did not pre-
vent E 2 -induced p38 activation ( fig. 5 F). In addition, IGF-
1 did not modify Ngb levels in SK-N-BE cells ( fig. 5 G) fur-
ther sustaining the high specificity of the E 2 effect.
Ngb
Tubulin
Ngb
Tubulin
Ngb
Tubulin
Ve
hi
cl
e
E 2 E 2
 +
 A
ct
A
ct Ve
hi
cl
e
E 2 E 2
 +
 C
xm
Cx
m
A
N
gb
 le
ve
l/
tu
bu
lin
 le
ve
l
(a
rb
itr
ar
y 
un
its
)
Vehicle E2 Act E2 + Act Vehicle E2 Cxm E2 + Cxm Vehicle E2 2-Br E2 + 2-Br
0
0.5
1.0
1.5
2.0
2.5
B
N
gb
 le
ve
l/
tu
bu
lin
 le
ve
l
(a
rb
itr
ar
y 
un
its
)
0
0.5
1.0
1.5
2.0
2.5
C
N
gb
 le
ve
l/
tu
bu
lin
 le
ve
l
(a
rb
itr
ar
y 
un
its
)
0
0.5
1.0
1.5
2.0
2.5
* * *
ºº º
Ve
hi
cl
e
E 2 2-
Br
E 2
 +
 2
-B
r
 Fig. 4. Mechanisms underlying E 2 effects on Ngb protein expres-
sion in SK-N-BE human neuroblastoma cells.  A Western blot 
analyses of Ngb levels in cells stimulated for 24 h with either ve-
hicle, E 2 (1 n M ) and/or the transcription inhibitor actinomycin D 
(Act, 1   g/ml).  B Analyses of Ngb levels in cells stimulated for
24 h with either vehicle, E 2 (1 n M ) and/or the translation inhibitor 
cycloheximide (Cxm, 10   g/ml).  C Analyses of Ngb levels in cells 
stimulated for 24 h with either vehicle, E 2 (1 n M ) and/or the pal-
mitoylacyl transferase inhibitor 2-bromohexadecanoic acid (2-Br; 
10   M ). The amount of proteins was normalized by comparison 
with tubulin levels. Data are representative Western blots of inde-
pendent experiments ( A – C top panels); densitometric analyses 
( A – C bottom panels). Data are means  8 SD of four different ex-
periments. p  !  0.001 was calculated with ANOVA followed by 
Tukey-Kramer post-test with respect to ( * ) vehicle- or (°) E 2 -treat-
ed samples. 
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 Fig. 5. Rapid signal transduction pathways activated by E 2 and 
impact of E 2 -dependent rapid signal inhibitors on Ngb protein 
levels in SK-N-BE human neuroblastoma cell line.  A Time-course 
analyses of phosphorylated (P) and unphosphorylated AKT, p38, 
and ERK1/2 in cells stimulated for 0, 15, 30, and 60 min with E 2 
(1 n M ).  B Densitometric analysis related to E 2 -induced AKT, p38, 
and ERK1/2 phosphorylation experiments. Data are means  8 SD 
of four different experiments.  *   p  !  0.001 was calculated with 
ANOVA followed by Tukey-Kramer post-test: a significant vs. 0, 
b vs. 15, and c vs. 30 min.  C ,  D Analyses of Ngb levels in cells 
stimulated for 1 h ( C ) or 24 h ( D ) with either vehicle, E 2 (1 n M ) and/
or the p38 inhibitor SB-203580 (SB; 5   M ).  E Analysis of Ngb, ER  , 
and phosphorylated (P) and unphosphorylated p38 levels in cells 
transfected with either MOCK (control) or ER  small interfer-
ence mRNA (si-ER  ) in the absence or presence of E 2 (1 n M ). The 
amount of proteins was normalized by comparison with tubulin 
levels. Data are representative Western blots of three independent 
experiments.  F Western blot analyses of phosphorylated (P) and 
unphosphorylated AKT and p38 levels in cells treated for 24 h 
with either vehicle, E 2 (1 n M ) or IGF-1 (100 ng/ml). When indi-
cated, cells were pretreated with the IGF-1 receptor inhibitor pic-
ropodophyllin (PPP; 100   M ).  G Analyses of Ngb protein levels in 
cells treated for 24 h with either vehicle, E 2 (1 n M ) or IGF-1 (100 
ng/ml). The amount of proteins was normalized by comparison 
with tubulin levels. Data are representative Western blots of three 
independent experiments. 
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 Fig. 6. E 2 effect on SK-N-BE human neuroblastoma cell line viabil-
ity.  A Cells were grown in the presence of either vehicle or E 2 
(1 n M ) and counted at the indicated time. Data are means  8 SD of 
five independent experiments carried out in duplicate.  B Cells 
were grown for 24 h in the presence of either vehicle, E 2 (1 n M ) or 
E 2 in the presence of the ER  -selective antagonist (R,R)-5,11-di-
ethyl-5,6,11,12-tetrahydro-2,8-chrysenediol (THC; 1   M ). After 
24 h, cells were stimulated with H 2 O 2 50   M (24 h of stimulation), 
and counted. Data are means  8 SD of five independent experi-
ments carried out in duplicate. p  ! 0.001 was calculated with 
ANOVA followed by Tukey-Kramer post-test: a significant vs. Ve-
hicle – H 2 O 2 , b vs. vehicle + H 2 O 2 , c vs. E 2 – H 2 O 2 , d vs. E 2 + H 2 O 2 , 
and e vs. THC + E 2 – H 2 O 2 .  C Western blot analyses of caspase-3 
activation and poly(ADP-ribose) polymerase (PARP) cleavage 
were performed on cells stimulated with either the vehicle or pre-
treated with E 2 (1 n M ) for 24 h in the presence or absence of THC 
pretreatment, and then treated with H 2 O 2 50   M (24 h of stimula-
tion). Staurosporin (2   M for 24 h) was used as positive control of 
caspase activation. The amount of proteins was normalized by 
comparison with tubulin level. Data are representative Western 
blots of three independent experiments.  D Western blot analysis of 
Ngb protein levels in cells transfected with either MOCK (control) 
or with Ngb small interference mRNA (si-Ngb) in the absence or 
presence of E 2 (1 n M ). The amount of proteins was normalized by 
comparison with tubulin levels. Data are representative Western 
blots of three independent experiments. Cells transfected with ei-
ther MOCK (empty bars) or si-Ngb (filled bars) were grown for 24 
h in the presence of either the vehicle or E 2 (1 n M ), stimulated with 
H 2 O 2 50   M (24 h of stimulation), and counted. Data are means 
 8 SD of three independent experiments carried out in duplicate. 
p  ! 0.001 was calculated with ANOVA followed by Tukey-Kramer 
post-test: a significant vs. vehicle – H 2 O 2 , b vs. vehicle + H 2 O 2 , 
c vs. E 2 + H 2 O 2 , d vs. vehicle – H 2 O 2 si-Ngb, and e vs. E 2 – H 2 O 2 
si-Ngb.  E Western blot analyses of caspase-3 activation and 
poly(ADP-ribose) polymerase (PARP) cleavage were performed 
on cells transfected with either MOCK or si-Ngb and stimulated 
with either vehicle or 50   M H 2 O 2 in the presence or absence of E 2 
(1 n M ) (24 h pretreatment). The amount of proteins was normal-
ized by comparison with tubulin level. Data are representative 
Western blots of three independent experiments. 
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 Ngb Involvement in E 2 -Induced Protection against 
H 2 O 2 -Induced Oxidative Stress 
 Finally we evaluated the role played by increased lev-
els of Ngb on E 2 effects in SK-N-BE cells. E 2 stimulation 
did not modify SK-N-BE cell number ( fig. 6 A) but, as ex-
pected  [61] , reduced by 50% the H 2 O 2 -induced decrease 
in cell number ( fig. 6 B) as well as the increase of the 17-
kDa active caspase-3 subunit and the cleavage of the cas-
pase-3 substrate PARP ( fig. 6 C). Staurosporin (2   M for 
24 h) was used as positive control of caspase activation 
( fig. 6 C). Notably, the E 2 -protective effect against H 2 O 2 -
induced neuron toxicity seems to require ER  , since the 
cell pretreatment with the specific ER  inhibitor THC 
completely prevented E 2 effects ( fig. 6 B, C). In line with 
this result, E 2 was unable to counteract the H 2 O 2 -in-
duced decrease in cell number ( fig. 6 D) and the activa-
tion of the pro-apoptotic cascade (i.e., caspase-3 activa-
tion and PARP cleavage) ( fig. 6 E) in Ngb-silenced SK-N-
BE cells.
 Discussion 
 The aim of this paper was to identify a possible endog-
enous modulator of Ngb. Thus, we investigated the effect 
of E 2 , a well-known neurotrophic and neuroprotective 
hormone  [52–57, 63–66] , on Ngb expression. Our results 
indicated that E 2 increases Ngb levels of about 300% in 
both the human neuroblastoma cell line and mouse pri-
mary hippocampal neurons. Although it has been ob-
tained with a qualitative technique (i.e., Western blot), 
this effect is conspicuous in that the well-known E 2 effect 
on cyclin D1 expression, playing a relevant role in E 2 -in-
duced cell proliferation, is only of about 50–70%  [67] . In 
addition, the E 2 -induced Ngb increase is rapid (1 h), per-
sistent (24 h), and specific, being not mimicked by either 
the male sex steroid hormone DHT or by the common 
precursor T or by IGF-1, another well-known neuropro-
tective hormone. These results represent the first evi-
dence for steroid hormone modulation of globin levels in 
cells. Recently, it has been reported that hemoglobin is 
specifically expressed in neurons, its expression being 
upregulated by erythropoietin and accompanied by en-
hanced brain oxygenation under physiologic and hypox-
ic conditions  [68] . At the present, the relationship be-
tween hemoglobin and Ngb in neurons is still unclear. 
Although hemoglobin   -chains and Ngb are expressed
in the same nerve cells, Ngb levels are not increased by 
erythropoietin  [68] . It is therefore unlikely that they have 
a tightly linked function, e.g. in facilitated oxygen trans-
port; however, hemoglobin and Ngb could fulfill inde-
pendent tasks in neurons.
 It is now well known that sex steroid hormones have 
numerous effects on the brain throughout the lifespan, 
beginning during gestation and continuing on into se-
nescence  [69] . However, the inability of Ngb to react with 
androgens renders Ngb a new E 2 target that should be 
added to the variety of E 2 -specific actions on the brain 
which include mood, locomotor activity, pain sensitivity, 
vulnerability to epilepsy, attentional mechanisms, and 
cognition  [64] .
 The E 2 effect on Ngb levels is rapid and dose-depen-
dent with the maximum effect at E 2 physiological con-
centration (i.e., 1–10 n M ). Notably, the E 2 dose-response 
curve results in being bell-shaped. This is typical for E 2 
 [70] , whose effects are mediated by two receptor isoforms. 
Accordingly, the plant-derived flavonoid Nar, which par-
tially blocks the rapid activities of ER   [58] , increased 
Ngb levels with a plateau at 1   M concentration. This re-
sult suggests a functional antagonism between the activ-
ities of ER  and ER  in neurons, as has been reported in 
other cell types  [71] .
 Although human neuroblastoma cell line and mouse 
primary hippocampal neurons express different levels of 
both ER isoforms, the effect of E 2 on Ngb levels specifi-
cally requires all ER  activities. In fact, ER  extranucle-
ar and genomic signals cross-talk each other to guarantee 
both the rapid (1 h) and the persistent (24 h) E 2 effects. In 
particular, the rapid (15 min) and persistent (24 h) ER  -
mediated p38 activation is required for E 2 -induced Ngb 
increase. The E 2 -dependent activation of p38, a mitogen-
activated protein kinase (MAPK) family component, 
seems to represent a conserved pathway in ER  -based E 2 
rapid signals. Indeed, the E 2 -induced ER  -mediated ac-
tivation of the p38/MAPK occurs in ER  -transfected 
HeLa cells and in ER  -containing rat myoblasts and co-
lon adenocarcinoma cells  [70, 72, 73] . This signaling 
pathway transduces different E 2 effects depending on the 
cell context. In fact, p38 activation is required for E 2 -in-
duced apoptosis of cancer cells  [72, 73] , for E 2 -induced 
gene transcription  [73] , and for E 2 -induced protection 
against oxidative stress in neuroblastoma cell line (pres-
ent results) and in rat myoblasts [Marino, unpubl. re-
sults]. Thus, although Ngb promoter does not contain 
any canonical ERE, it is not surprising that the transcrip-
tion inhibitor Act completely prevents the increase of the 
E 2 -induced Ngb levels. The sequence analysis (accession 
No. 12,581 from Transcriptional Regulatory Element
Database http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?
process=home) indicates that several non-canonical half 
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ERE sites are present in the Ngb promoter along with a 
responsive element for other transcription factors. These 
results suggest that the E 2 -induced Ngb transcription 
could be mediated by tethered interactions of ER with 
other transcription factors to activate gene expression 
(i.e., indirect genomic mechanism)  [48] . Thus, the inte-
gration between extranuclear and genomic events may be 
required to provide plasticity for the neuronal response 
to E 2 . The hormone rapidly induces AKT activation and 
ERK dephosphorylation in neuroblastoma cells. These 
effects are still detected in ER  -containing but ER  -si-
lenced cells. Although these kinases are not directly in-
volved in an E 2 -induced Ngb increase, they could con-
tribute to the E 2 effects in neurons, since AKT activation 
has been associated with the increase of the anti-
apoptotic protein Bcl-2 and to the E 2 -induced cell sur-
vival  [72] , while E 2 protected cortical neurons against ox-
idative stress by reducing H 2 O 2 -induced activation of 
ERK1/2  [61] .
 The main result reported here is that Ngb is part of the 
E 2 response to H 2 O 2 -induced toxicity. In fact, exposure 
to 50   M H 2 O 2 induces neuroblastoma cell death (about 
50%) which is accompanied by a dramatic increase in cas-
pase-3 activation. The cell pretreatment with E 2 (1 n M ) 
decreases cell death and reduces caspase-3 activation 
triggered by exposure to H 2 O 2 in good accordance with 
the literature  [52–54, 61, 74] . This E 2 effect against H 2 O 2 
toxicity is completely prevented by treatment with THC, 
ER  inhibitor, and by knocking out Ngb using small in-
terfering RNA.
 Exposure to H 2 O 2 induces a robust increase of reactive 
oxygen species in cells (followed by oxidation of lipids, 
proteins, and DNA), intracellular calcium increase, glu-
tathione depletion, mitochondria dysfunction, and cas-
pase-3 activation followed by apoptotic cell death  [74] . It 
has been demonstrated that E 2 exerts protective effects on 
several of these cellular events including potent attenua-
tion of lipid peroxidation, attenuated ATP depletion, al-
leviated intracellular calcium elevation, ablated mito-
chondrial calcium loading (with the subsequent mito-
chondrial membrane potential maintenance), reduced 
caspase-3 activation, and enhanced cell survival ( [74] and 
present results). At present, it is difficult to discriminate 
the role played by Ngb in each of these E 2 -induced cellu-
lar outcomes because it is not yet clear if they require ER  
or ER  or both receptors. Moreover, most of the E 2 -pro-
tective effects have been obtained at pharmacological E 2 
concentrations (0.1–10   M )  [74] . However, it has recently 
shown that the elevation of human Ngb expression in 
neurons prior to insult with H 2 O 2 enhances cell viability 
and results in a significant decrease in oxidative stress 
and an increased intracellular ATP concentration  [75] . In 
addition, a linkage of Ngb to oxidative metabolism has 
been proposed  [76] . These data are strongly suggestive of 
the involvement of Ngb in E 2 -induced attenuated ATP 
depletion. Furthermore, in the presence of Ngb the ini-
tially released cytochrome  c  may be sequestered by the 
Ngb  [42, 43] and the apoptotic cascade avoided  [19] .
 In the future, different strategies (e.g., E 2 -induced Ngb 
localization, association between Ngb and ERs, and E 2 -
induced ER-mediated Ngb promoter activity) will sub-
stantiate Ngb action in neurons, our laboratories being 
active in this field. However, from now, Ngb can be re-
garded as part of signals activated by E 2 to exert neuro-
protective effects definitely validating the role played by 
Ngb as an anti-apoptotic neuroprotective globin.
 Acknowledgements 
 The generous gift of SK-N-BE human neuroblastoma cell line 
from Dr. Roberto Rivabene (Institute of Public Health, ISS, Rome, 
Italy) and of staurosporin from Dr. Antonio Antoccia (University 
Roma Tre) are gratefully acknowledged. This work was supported 
by grants from University Roma Tre (CLAR 2009 to P.A.) and the 
Italian Ministry of Health (Strategico 2008 to M.M).
 
 References 
 1 Burmester T, Weich B, Reinhardt S, Hankeln 
T: A vertebrate globin expressed in brain. 
Nature 2000; 407: 520–523. 
 2 Moens L, Dewilde S: Globins in the brain. 
Nature 2000; 407: 461–462. 
 3 Trent JT 3rd, Watts RA, Hargrove MS: Hu-
man neuroglobin, a hexacoordinate hemo-
globin that reversibly binds oxygen. J Biol 
Chem 2001; 276: 30106–30110. 
 4 Pesce A, Bolognesi M, Bocedi A, Ascenzi P, 
Dewilde S, Moens L, Hankeln T, Burmester 
T: Neuroglobin and cytoglobin. Fresh blood 
for the vertebrate globin family. EMBO Rep 
2002; 3: 1146–1151. 
 5 Reuss S, Saaler-Reinhardt S, Weich B, Wys-
tub S, Reuss MH, Burmester T, Hankeln T: 
Expression analysis of neuroglobin mRNA 
in rodent tissues. Neurosci 2002; 115: 645–
656. 
 6 Pesce A, Dewilde S, Nardini M, Moens L, As-
cenzi P, Hankeln T, Burmester T, Bolognesi 
M: Human brain neuroglobin structure re-
veals a distinct mode of controlling oxygen 
affinity. Structure 2003; 11: 1087–1095. 
 7 Wystub S, Laufs T, Schmidt M, Burmester
T, Maas U, Saaler-Reinhardt S, Hankeln T, 
Reuss S: Localization of neuroglobin protein 
in the mouse brain. Neurosci Lett 2003; 346: 
 114–116. 
 De Marinis  /Ascenzi  /Pellegrini  /Galluzzo  /
Bulzomi  /Arevalo  /Garcia-Segura  /Marino 
Neurosignals 2010;18:223–235234
 8 Burmester T, Hankeln T: Neuroglobin: a re-
spiratory protein of the nervous system. 
News Physiol Sci 2004; 19: 110–113. 
 9 Hankeln T, Wystub S, Laufs T, Schmidt M, 
Gerlach F, Saaler-Reinhardt S, Reuss S, Bur-
mester T: The cellular and subcellular local-
ization of neuroglobin and cytoglobin – a 
clue to their function? IUBMB Life 2004; 56: 
 671–679. 
 10 Vallone B, Nienhaus K, Matthes A, Brunori 
M, Nienhaus GU: The structure of carbon-
monoxy neuroglobin reveals a heme-sliding 
mechanism for control of ligand affinity. 
Proc Natl Acad Sci USA 2004; 101: 17351–
17356. 
 11 Hankeln T, Ebner B, Fuchs C, Gerlach F, 
Haberkamp M, Laufs TL, Roesner A, 
Schmidt M, Weich B, Wystub S, Saaler-Rein-
hardt S, Reuss S, Bolognesi M, De Sanctis D, 
Marden MC, Kiger L, Moens L, Dewilde S, 
Nevo E, Avivi A, Weber RE, Fago A, Bur-
mester T: Neuroglobin and cytoglobin in 
search of their role in the vertebrate globin 
family. J Inorg Biochem 2005; 99: 110–119. 
 12 Brunori M, Vallone B: A globin for the brain. 
FASEB J 2006; 20: 2192–2197. 
 13 Nienhaus K, Nienhaus GU: Searching for 
neuroglobin’s role in the brain. IUBMB Life 
2007; 59: 490–497. 
 14 Greenberg DA, Jin K, Khan AA: Neuroglo-
bin: an endogenous neuroprotectant. Curr 
Opin Pharmacol 2008; 8: 20–24. 
 15 Burmester T, Hankeln T: What is the func-
tion of neuroglobin? J Exp Biol 2009; 212: 
 1423–1428. 
 16 Yu Z, Fan X, Lo EH, Wang X: Neuroprotec-
tive roles and mechanisms of neuroglobin. 
Neurol Res 2009; 31: 122–127. 
 17 Emara M, Turner AR, Allalunis-Turner J: 
Hypoxic regulation of cytoglobin and neu-
roglobin expression in human normal and 
tumor tissues. Cancer Cell Int 2010; 10: 33–
49. 
 18 Hundahl CA, Allen GC, Hannibal J, Kjaer K, 
Rehfeld JF, Dewilde S, Nyengaard JR, Kelsen 
J, Hay-Schmidt A: Anatomical characteriza-
tion of cytoglobin and neuroglobin mRNA 
and protein expression in the mouse brain. 
Brain Res 2010; 1331: 58–73. 
 19 Fago A, Mathews AJ, Brittain T: A role for 
neuroglobin: resetting the trigger level for 
apoptosis in neuronal and retinal cells. 
IUBMB Life 2008; 60: 398–401. 
 20 Schmidt M, Giessl A, Laufs T, Hankeln T, 
Wolfrum U, Burmester T: How does the eye 
breathe? Evidence for neuroglobin-mediated 
oxygen supply in the mammalian retina. J 
Biol Chem 2003; 278: 1932–1935. 
 21 Bentmann A, Schmidt M, Reuss S, Wolfrum 
U, Hankeln T, Burmester T: Divergent distri-
bution in vascular and avascular mammali-
an retinae links neuroglobin to cellular res-
piration. J Biol Chem 2005;  280:  20660–
20665. 
 22 Dewilde S, Kiger L, Burmester T, Hankeln T, 
Baudin-Creuza V, Aerts T, Marden MC, 
Caubergs R, Moens L: Biochemical charac-
terization and ligand binding properties of 
neuroglobin, a novel member of the globin 
family. J Biol Chem 2001; 276: 38949–38955. 
 23 Hamdane D, Kiger L, Dewilde S, Green BN, 
Pesce A, Uzan J, Burmester T, Hankeln T, 
Bolognesi M, Moens L, Marden MC: The re-
dox state of the cell regulates the ligand bind-
ing affinity of human neuroglobin and cyto-
globin. J Biol Chem 2003; 278: 51713–51721. 
 24 Fago A, Hundahl C, Malte H, Weber RE: 
Functional properties of neuroglobin and 
cytoglobin: insights into the ancestral physi-
ological roles of globins. IUBMB Life 2004; 
 56: 689–696. 
 25 Herold S, Fago A, Weber RE, Dewilde S, 
Moens L: Reactivity studies of the Fe(III) and 
Fe(II)NO forms of human neuroglobin re-
veal a potential role against oxidative stress. 
J Biol Chem 2004; 279: 22841–22847. 
 26 Kiger L, Uzan J, Dewilde S, Burmester T, 
Hankeln T, Moens L, Hamdane D, Baudin-
Creuza V, Marden M: Neuroglobin ligand 
binding kinetics. IUBMB Life 2004; 56: 709–
719. 
 27 Trandafir F, van Doorslaer S, Dewilde S, 
Moens L: Temperature dependence of NO 
binding modes in human neuroglobin. Bio-
chim Biophys Acta 2004; 1702: 153–161. 
 28 Brunori M, Giuffré A, Nienhaus K, Nienhaus 
GU, Scandurra FM, Vallone B: Neuroglobin, 
nitric oxide, and oxygen: functional path-
ways and conformational changes. Proc Natl 
Acad Sci USA 2005; 102: 8483–8488. 
 29 Fago A, Mathews AJ, Dewilde S, Moens L, 
Brittain T: The reactions of neuroglobin with 
CO: evidence for two forms of the ferrous 
protein. J Inorg Biochem 2006; 100: 1339–
1343. 
 30 Nicolis S, Monzani E, Ciaccio C, Ascenzi P, 
Moens L, Casella L: Reactivity and endoge-
nous modification by nitrite and hydrogen 
peroxide: does human neuroglobin act only 
as a scavenger? Biochem J 2007; 407: 89–99. 
 31 Brittain T, Yosaatmadja Y, Henty K: The in-
teraction of human neuroglobin with hydro-
gen sulphide. IUBMB Life 2008; 60: 135–138. 
 32 Giuffrè A, Moschetti T, Vallone B, Brunori 
M: Neuroglobin: enzymatic reduction and 
oxygen affinity. Biochem Biophys Res Com-
mun 2008; 367: 893–898. 
 33 Kakar S, Hoffman FG, Storz JF, Fabian M, 
Hargrove MS: Structure and reactivity of 
hexacoordinate hemoglobins. Biophys 
Chem 2010; 152: 1–14. 
 34 Ostojić J, Sakaguchi DS, de Lathouder Y, 
Hargrove MS, Trent JT 3rd, Kwon YH, Kar-
don RH, Kuehn MH, Betts DM, Grozdanić S: 
Neuroglobin and cytoglobin: oxygen-bind-
ing proteins in retinal neurons. Invest Oph-
thalmol Vis Sci 2006; 47: 1016–1023. 
 35 Herold S, Fago A: Reactions of peroxynitrite 
with globin proteins and their possible phys-
iological role. Comp Biochem Physiol A Mol 
Integr Physiol 2005; 142: 124–129. 
 36 Petersen MG, Dewilde S, Fago A: Reactions 
of ferrous neuroglobin and cytoglobin with 
nitrite under anaerobic conditions. J Inorg 
Biochem 2008; 102: 1777–1782. 
 37 Jin K, Mao XO, Xie L, Khan AA, Greenberg 
DA: Neuroglobin protects against nitric ox-
ide toxicity. Neurosci Lett 2008; 430: 135–137. 
 38 Fordel E, Thijs L, Moens L, Dewilde S: Neu-
roglobin and cytoglobin expression in mice. 
Evidence for a correlation with reactive oxy-
gen species scavenging. FEBS J 2007; 274: 
 1312–1317. 
 39 Khan AA, Mao XO, Banwait S, DerMardi-
rossian CM, Bokoch GM, Jin K, Greenberg 
DA: Regulation of hypoxic neuronal death 
signaling by neuroglobin. FASEB J 2008; 22: 
 1737–1747. 
 40 Watanabe S, Wakasugi K: Neuroprotective 
function of human neuroglobin is correlated 
with its guanine nucleotide dissociation in-
hibitor activity. Biochem Biophys Res Com-
mun 2008; 369: 695–700. 
 41 Fago A, Mathews AJ, Moens L, Dewilde S, 
Brittain T: The reaction of neuroglobin with 
potential redox protein partners cytochrome 
 b 5 and cytochrome  c . FEBS Lett 2006; 580: 
 4884–4888. 
 42 Brittain T, Skommer J, Raychaudhuri S, 
Birch N: An antiapoptotic neuroprotective 
role for neuroglobin. Int J Mol Sci 2010; 11: 
 2306–2231. 
 43 Raychaudhuri S, Skommer J, Henty K, Birch 
N, Brittain T: Neuroglobin protects nerve 
cells from apoptosis by inhibiting the intrin-
sic pathway of cell death. Apoptosis 2010; 15: 
 401–411. 
 44 Pesce A, De Sanctis D, Nardini M, Dewilde 
S, Moens L, Hankeln T, Burmester T, Ascen-
zi P, Bolognesi M: Reversible hexa- to penta-
coordination of the heme Fe atom modulates 
ligand binding properties of neuroglobin 
and cytoglobin. IUBMB Life 2004; 56: 657–
664. 
 45 Sun Y, Jin K, Peel A, Mao XO, Xie L, Green-
berg DA: Neuroglobin protects the brain 
from experimental stroke in vivo. Proc Natl 
Acad Sci USA 2003; 100: 3497–3500. 
 46 Khan AA, Wang Y, Sun Y, Mao XO, Xie L, 
Miles E, Graboski J, Chen S, Ellerby LM,
Jin K, Greenberg DA: Neuroglobin-overex-
pressing transgenic mice are resistant to ce-
rebral and myocardial ischemia. Proc Natl 
Acad Sci USA 2006; 103: 17944–17948. 
 47 Jin K, Mao Y, Mao X, Xie L, Greenberg DA: 
Neuroglobin expression in ischemic stroke. 
Stroke 2010; 41: 557–559. 
 48 Ascenzi P, Bocedi A, Marino M: Structure-
function relationship of estrogen receptor   
and   : impact on human health. Mol Aspects 
Med 2006; 27: 299–402. 
 49 Manthey D, Behl C: From structural bio-
chemistry to expression profiling: neuropro-
tective activities of estrogen. Neuroscience 
2006; 138: 845–850. 
 17  -Estradiol Signaling and Neuroglobin Neurosignals 2010;18:223–235 235
 50 Correia SC, Santos RX, Cardoso S, Carvalho 
C, Santos MS, Oliveira CR, Moreira PI: Ef-
fects of estrogen in the brain: is it a neuropro-
tective agent in Alzheimer’s disease? Curr 
Aging Sci 2010; 3: 113–126. 
 51 Gillies GE, McArthur S: Estrogen actions in 
the brain and the basis for differential action 
in men and women: a case for sex-specific 
medicines. Pharmacol Rev 2010; 62: 155–198. 
 52 Behl C, Skutella T, Lezoualc’h F, Post A, 
Widmann M, Newton CJ, Holsboer F: Neu-
roprotection against oxidative stress by es-
trogens: structure-activity relationship. Mol 
Pharmacol 1997; 51: 535–541. 
 53 Sawada H, Ibi M, Kihara T, Urushitani M, 
Akaike A, Shimohama S: Estradiol protects 
mesencephalic dopaminergic neurons from 
oxidative stress-induced neuronal death. J 
Neurosci Res 1998; 54: 707–719. 
 54 Green PS, Simpkins JW: Neuroprotective ef-
fects of estrogens: potential mechanisms of 
action. Int J Dev Neurosci 2000; 18: 347–358. 
 55 Bae YH, Hwang JY, Kim YH, Koh JY: Anti-
oxidative neuroprotection by estrogens in 
mouse cortical cultures. J Korean Med Sci 
2000; 15: 327–336. 
 56 Wilson ME, Dubal DB, Wise PM: Estradiol 
protects against injury-induced cell death in 
cortical explant cultures: a role for estrogen 
receptors. Brain Res 2000; 873: 235–242. 
 57 Blum-Degen D, Haas M, Pohli S, Harth R, 
Romer W, Oettel M, Riederer P, Gotz ME: 
Scavestrogens protect IMR 32 cells from ox-
idative stress-induced cell death. Toxicol 
Appl Pharmacol 1998; 152: 49–55. 
 58 Galluzzo P, Ascenzi P, Bulzomi P, Marino M: 
The nutritional f lavanone naringenin trig-
gers antiestrogenic effects by regulating es-
trogen receptor   -palmitoylation. Endocri-
nology 2008; 149: 2567–2575. 
 59 Totta P, Acconcia F, Leone S, Cardillo I, Ma-
rino M: Mechanisms of naringenin-induced 
apoptotic cascade in cancer cells: involve-
ment of estrogen receptor   and   signalling. 
IUBMB Life 2004; 56: 491–499. 
 60 Acconcia F, Ascenzi P, Bocedi A, Spisni E, 
Tomasi V, Trentalance A, Visca P, Marino M: 
Palmitoylation-dependent estrogen receptor 
  membrane localization: regulation by 17  -
estradiol. Mol Biol Cell 2005; 16: 231–237. 
 61 Numakawa Y, Matsumoto T, Yokomaku D, 
Taguchi T, Niki E, Hatanaka H, Kunugi H, 
Numakawa T: 17  -Estradiol protects corti-
cal neurons against oxidative stress-induced 
cell death through reduction in the activity 
of mitogen-activated protein kinase and in 
the accumulation of intracellular calcium. 
Endocrinology 2007; 148: 627–637. 
 62 Marin R, Diaz M, Alonso R, Sanz A, Arevalo 
MA, Garcia-Segura LM: Role of estrogen re-
ceptor   in membrane-initiated signaling in 
neural cells: interaction with IGF-1 receptor. 
J Steroid Biochem Mol Biol 2009; 114: 2–7. 
 63 Regan RF, Guo Y: Estrogens attenuate neu-
ronal injury due to hemoglobin, chemical 
hypoxia and excitatory amino acids in mu-
rine cortical cultures. Brain Res 1997; 764: 
 133–140. 
 64 McEwen BS: Sex, stress and the hippocam-
pus: allostasis, allostatic load and the aging 
process. Neurobiol Aging 2002; 23: 921–939. 
 65 Marin R, Ramirez C, Morales A, Gonzalez 
M, Alonso R, Diaz M: Modulation of A  -in-
duced neurotoxicity by estrogen receptor   
and other associated proteins in lipid rafts. 
Steroids 2008; 73: 992–996. 
 66 Vasudevan N, Pfaff DW: Non-genomic ac-
tions of estrogens and their interaction with 
genomic actions in the brain. Front Neuro-
endocrinol 2008; 29: 238–257. 
 67 Marino M, Acconcia F, Bresciani F, Weisz A, 
Trentalance A: Distinct nongenomic signal 
transduction pathways controlled by 17  -
estradiol regulate DNA synthesis and cyclin 
D 1 gene transcription in HepG2 cells. Mol 
Biol Cell 2002; 13: 3720–3729. 
 68 Schelshorn DW, Schneider A, Kuschinsky 
W, Weber D, Kruger C, Dittgen T, Bourgers 
HF, Sabouri F, Gassler N, Bach A, Maurer 
MH: Expression of hemoglobin in rodent 
neurons. J Cereb Blood Flow Metab 2009; 29: 
 585–595. 
 69 Swaab DF: Sexual differentiation of the brain 
and behavior. Best Pract Res Clin Endo Me-
tabol 2007; 21: 431–444. 
 70 Galluzzo P, Rastelli C, Bulzomi P, Acconcia 
F, Pallottini V, Marino M: 17  -Estradiol reg-
ulates the first steps of skeletal muscle cell 
differentiation via ER  -mediated signals. 
Am J Physiol Cell Physiol 2009; 297:C1249–
C1262. 
 71 Matthews J, Gustafsson JA: Estrogen signal-
ling: a subtle balance between ER  and ER  . 
Mol Intervent 2003; 3: 281–292. 
 72 Acconcia F, Totta P, Ogawa S, Cardillo I,
Inoue S, Leone S, Trentalance A, Muramatsu 
M, Marino M: Survival versus apoptotic 
17  -estradiol effect: role of ER  - and ER  -
activated nongenomic signaling. J Cell 
Physiol 2005; 203: 193–201. 
 73 Galluzzo P, Caiazza F, Moreno S, Marino M: 
Role of ER  palmitoylation in the inhibition 
of human colon cancer cell proliferation. En-
docr Relat Cancer 2007; 14: 153–167. 
 74 Wang X, Dykens JA, Perez E, Liu R, Yang S, 
Covey DF, Simpkins JW: Neuroprotective ef-
fects of 17  -estradiol and nonfeminizing es-
trogens against H 2 O 2 toxicity in human neu-
roblastoma SK-N-SH cells. Mol Pharmacol 
2006; 70: 395–404. 
 75 Antao ST, Duong TT, Aran R, Witting PK: 
Neuroglobin overexpression in cultured hu-
man neuronal cells protects against hydro-
gen peroxide insult via activating phos-
phoinositide-3 kinase and opening the mito-
chondrial K(ATP) channel. Antioxid Redox 
Signal 2010; 13: 769–781. 
 76 Mitz SA, Reuss S, Folkow LP, Blix AS, 
Ramirez JM, Hankeln T, Burmester T: When 
the brain goes diving: glial oxidative metab-
olism may confer hypoxia tolerance to the 
seal brain. Neurosci 2009; 163: 552–560. 
 
